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De Novo and Inherited Pathogenic Variants in KDM3B
Cause Intellectual Disability, Short Stature, and
Facial Dysmorphism
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Isabelle Thiffault,14,15,16 Maxime Cadieux-Dion,14,15 Lina Huerta-Saenz,17,18 Matias Wagner,19,20,21
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Han G. Brunner,1,25,26 Tjitske Kleefstra,1,25 Nicoline Hoogerbrugge,1 Bert B.A. de Vries,1 Vivian Hwa,3
Andrew Dauber,3,27 Jayne Y. Hehir-Kwa,2 Roland P. Kuiper,1,2 and Marjolijn C.J. Jongmans1,2,13,*
By using exome sequencing and a gene matching approach, we identified de novo and inherited pathogenic variants in KDM3B in 14
unrelated individuals and three affected parents with varying degrees of intellectual disability (ID) or developmental delay (DD) and
short stature. The individuals share additional phenotypic features that include feeding difficulties in infancy, joint hypermobility,
and characteristic facial features such as a wide mouth, a pointed chin, long ears, and a low columella. Notably, two individuals devel-
oped cancer, acute myeloid leukemia and Hodgkin lymphoma, in childhood. KDM3B encodes for a histone demethylase and is involved
in H3K9 demethylation, a crucial part of chromatin modification required for transcriptional regulation. We identified missense and
truncating variants, suggesting that KDM3B haploinsufficiency is the underlying mechanism for this syndrome. By using a
hybrid facial-recognition model, we show that individuals with a pathogenic variant in KDM3B have a facial gestalt, and that
they show significant facial similarity compared to control individuals with ID. In conclusion, pathogenic variants in KDM3B cause a
syndrome characterized by ID, short stature, and facial dysmorphism.
Intellectual disability (ID) and autism spectrum disorder
are neurodevelopmental disorders (NDDs) that occur in
approximately 1%–3% of the general population.1,2 The
introduction of next-generation sequencing techniques
as a diagnostic test for individuals with unexplained
NDD has led to the discovery of many disease-causing
mutations in genes previously unassociated with dis-
ease.3–6 However, a subset of individuals remain without
a diagnosis. By using trio-based exome sequencing in
diagnostic or research settings as described before,5,7–10
and by collaborating via GeneMatcher,11 we identified
17 individuals with heterozygous missense and trun-
cating variants in KDM3B (lysine-specific demethylase
3B [MIM: 609373; GenBank: NM_016604.3]; Figure 1A).
All 14 different variants found were absent from the gno-
mAD and ExAC databases, and 13/14 had high Combined
Annotation Dependent Depletion scores (CADD; scores
between 13 and 40) and were predicted to be pathogenic
by both the PolyPhen-2 and SIFT prediction programs
(Table 1).12–15 All individuals or their legal guardians
gave written informed consent, and the study was given
IRB approval.
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In ten individuals, the variants identifiedwere confirmed
to be de novo, and in three other individuals (individuals 1,
6, and 16) the variants were inherited from similarly
affected parents (individuals 2, 7, and 17), summing up to
16 individuals. In one additional individual with a pro-
tein-truncating variant (individual 14), no paternal DNA
was available for segregation analysis, but we confirmed
that the variant was not maternally inherited. Phenotypic
data for the individuals is shown in Table 2 and Table S1.
The 17 individuals (9 females and 8 males) were all diag-
nosed with developmental delay (DD) or mild to moderate
ID, although one individual (individual 14) was too young
for development to be assessed. The individuals show both
delayedmotor anddelayed speechdevelopments, although
the language delays are more pronounced. Behavior prob-
lems were noted in eight individuals: there was a diagnosis
of attention deficit hyperactivity disorder (ADHD) in four
Figure 1. KDM3B Germline Variants and
Amino Acid Sequence Conservation
(A) A schematic representation of KDM3B,
including the zinc-finger domain, LXLL
motif, and Jumonji-C domain, showing
the location of the reported variants ac-
cording to their position at the protein
level. The gray lollipops represent the vari-
ants that were inherited from similarly
affected parents. As indicated, truncating
variants were identified in five individuals
and missense variants in 12 individuals.
(B) A tolerance landscape plot provided by
the MetaDome web server for the analysis
of KDM3B. For quantifying genetic toler-
ance, a missense-over-synonymous ratio
based on the variations reported in the
gnomAD database is calculated. This ratio
is computed into a tolerance landscape
as a sliding window of 11 residues over
the protein.30 For KDM3B, this plot
shows intolerance for missense variation
in and nearby the zinc-finger and
Jumonji-C domains, where most of the
missense mutations identified in the indi-
viduals described in this paper are located.
(C) Protein alignment of KDM3B orthologs
across several species. Additionally, we
aligned JMJD1C and KDM3A. These pro-
teins show homology with KDM3B and
share the same functional domains. As
shown, the Trp117, Arg943, Arg1028,
Asp1032, Leu1509, Tyr1544, Glu1731,
and Leu1734 positions (shown in red) are
evolutionarily highly conserved.
individuals and a diagnosis of autism
spectrum disorder in three individ-
uals. Notably, two individuals had a
double diagnosis of autism spectrum
disorder combined with ADHD. Three
other individuals showed aggressive
behavior, hyperactivity, and delayed
social-emotional development, but
they did not have formal psychiatric
diagnoses. Other neurological problems included epilepsy
in three individuals and childhood hypotonia in five indi-
viduals. In two out of three individuals with epilepsy, the
epilepsy showed a transient character.
Eight individuals presented with short stature, defined as
a height below 2.5 SD. Microcephaly was reported in one
individual, whereas the others had normal head circumfer-
ences. Other recurrent features included neonatal feeding
difficulties (n ¼ 9), eye abnormalities (n ¼ 5), hearing
loss (n ¼ 4), joint hypermobility (n ¼ 5), and hematologi-
cal malignancies (n ¼ 2). The eye abnormalities consisted
of ocular movement disorders such as nystagmus and stra-
bismus in four individuals and refraction anomalies and
low vision in three individuals. Furthermore, the individ-
uals displayed a wide range of congenital anomalies,
including umbilical and inguinal hernias, cryptorchidism,
hypospadia, ventricular septal defect, interrupted inferior
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vena cava, diaphragmatic hernia, heterotaxy, duodenal
atresia, pulmonary capillary hemangiomatosis, and
congenital hip dysplasia. With the exception of the umbil-
ical hernia, the inguinal hernia, and the diaphragmatic
hernia (all three present in two individuals), none of the
congenital anomalies were recurrent in multiple individ-
uals. No clear genotype-phenotype correlation could be
observed. Shared facial characteristics in the majority of
the individuals were long ears (n ¼ 9), a broad nasal tip
(n ¼ 14), a low-hanging columella (n ¼ 6), a wide mouth
(n ¼ 12), a thin upper lip vermillion (n ¼ 12), and a
pointed chin (n ¼ 12), as shown in Figure 2.
On the basis of these shared dysmorphic features, we hy-
pothesized that facial recognition software would be able
to detect common facial features in individuals with
missense and truncating variants in KDM3B. Facial recog-
nition software is able to objectively detect subtle features
whichmight be difficult to identify by eye.16–18 In the past,
facial recognition software has been used to objectively
measure dysmorphic features in individuals with various
syndromes.17–19 We collected and analyzed photographs
of 13 out of 14 children. The three affected parents were
deliberately excluded to avoid a bias caused by facial fea-
tures that were shared with their children and unrelated
to the variant identified. To determine whether a facial
gestalt is present in individuals with a variant in KDM3B,
we used a hybrid model recently developed and described
by van der Donk et al.20 This hybrid model combines the
output of two computer vision algorithms: Clinical Face
Phenotype Space (CFPS)21 and OpenFace.22 In this hybrid
method, the resulting two output feature vectors from
these algorithms are combined, giving a 468-dimensional
hybrid feature vector that represents the facial features of
an individual. Because the CFPS and OpenFace algorithms
were trained to recognize dysmorphic features and general
facial features, respectively, both algorithms recognize
different facial characteristics, and the combined hybrid
model uses both of these different feature types to improve
the distinction between subtle differences in these dysmor-
phic features (details in van der Donk et al.20).
To determine the similarity between individuals with a
variant in KDM3B versus a control population consisting
of 130 individuals with other ID-syndromes, we calculated
the clustering improvement factors (CIFs), which give an
estimate of search space reduction.21 In brief, the CIF esti-
mates how a group of affected individuals cluster within a
group of controls and compares that clustering to what is
expected by random chance. For each individual, ten ID-
affected controls that were matched for age, gender, and
ethnicity were selected. We used ID-affected controls
instead of healthy control individuals so that we could
determine whether we are able to distinguish individuals
with a variant in KDM3B from the general ID-affected
population.
Table 1. In Silico Analysis of KDM3B Variants Identified
Ind.
mRNA
Change
Predicted
Protein Effect Inheritance gnomAD PhyloP CADD Score PolyPhen-2 SIFT
MetaDome
Tolerancea
1 c.133C>T p.Arg45* de novo 0 4.08 38 NA NA NA
2 c.277G>T p.Glu93* maternal 0 4.00 35 NA NA NA
3b c.277G>T p.Glu93* ND 0 4.00 35 NA NA NA
4 c.349T>C p.Trp117Arg de novo 0 3.35 20.2 probably damaging deleterious neutral
5 c.1007A>G p.Asp336Gly maternal 0 2.06 13.8 benign deleterious tolerant
6b c.1007A>G p.Asp336Gly ND 0 2.06 13.8 benign deleterious tolerant
7 c.2479C>T p.Gln827* ND 0 2.79 33 NA NA NA
8 c.2827C>T p.Arg943Trp de novo 0 4.32 25.9 probably damaging deleterious intolerant
9 c.2828G>A p.Arg943Gln de novo 0 6.34 36 probably damaging deleterious intolerant
10 c.3083G>A p.Arg1028Gln de novo 0 6.18 37 probably damaging deleterious highly intolerant
11 c.3095A>T p.Asp1032Val de novo 0 4.97 32 probably damaging deleterious highly intolerant
12 c.4526T>C p.Leu1509Pro de novo 0 4.81 23.2 probably damaging deleterious intolerant
13 c.4549C>T p.Arg1517* de novo 0 2.55 40 NA NA NA
14 c.4631A>G p.Tyr1544Cys de novo 0 4.97 23 probably damaging deleterious highly intolerant
15 c.5191G>A p.Glu1731Lys paternal 0 6.26 23.5 probably damaging deleterious intolerant
16b c.5191G>A p.Glu1731Lys ND 0 6.26 23.5 probably damaging deleterious intolerant
17 c.5201T>G p.Leu1734Arg de novo 0 5.13 18 probably damaging deleterious intolerant
Abbreviations are as follows: Ind. ¼ individual; CADD ¼ Combined Annotation Dependent Depletion; SIFT ¼ Sorting Intolerant From Tolerant; ND ¼ not deter-
mined; and NA ¼ not applicable.
aThe MetaDome tolerance is based on the tolerance colors of the web server MetaDome.30
bIndividuals 3, 6, and 16 are the mother, father, and mother of individuals 2, 5, and 15, respectively.
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We performed a permutation test by randomly labeling
10,000 case-control serieswithinour dataset. Subsequently,
we calculated the corresponding CIFs for each permutation
by using the hybrid model, and we used right-tailedMann-
Whitney U tests to determine whether the CIF for the
KDM3B individuals was significantly higher than expected
based on random chance. By using this approach, we
were able to demonstrate that there is a significant similar-
ity between the faces of individuals with a germline variant
in KDM3B when compared to the general ID population
(CIF¼ 2.5962; p¼ 0.0054; Figure 3). This strongly suggests
that the individuals with a variant in KDM3B have a facial
gestalt, and that the computational analysis of facial dys-
morphisms can be used to delineate this genetic entity. In
the future, when combined with other phenotypic and ge-
netic information, this hybrid facial recognition model
might be useful for classifying individuals with variants of
unknown significance (VUSs) in KDM3B.
Table 2. Clinical Characteristics of Individuals with KDM3B Variants
Percentage Number
Development
Intellectual disability or developmental delay 94.1% 16/17a
Developmental delay 23.5% 4/17
Mild disability 47.1% 8/17
Mild to moderate or moderate disability 23.5% 4/17
Growth
Short stature (<2.5 SD) 50.0% 8/16
Height <1.5 SD 68.8% 11/16
Neurological
Behavior problems 53.3% 8/15b
ADHD 26.7% 4/15
Autism spectrum disorder 20.0% 3/15
Other 13.3% 2/15
Epilepsy 20.0% 3/15
Childhood hypotonia 38.5% 5/13
Congenital Anomalies
Umbilical hernia 12.5% 2/16
Inguinal hernia 12.5% 2/16
Cryptorchidism 12.5% 1/8
Hypospadia 12.5% 1/8
Congenital hip dysplasia 6.3% 1/16
Congenital hypothyroidism 6.3% 1/16
Diaphragmatic hernia 12.5% 2/16
Heterotaxy 6.3% 1/16
Interrupted inferior vena cava 6.3% 1/16
Duodenal atresia 6.3% 1/16
Other
Neonatal feeding difficulties 60% 9/15
Joint hypermobility 31.3% 5/16
Eye abnormalities 31.3% 5/16
Hearing loss 23.5% 4/17
Malignancy 11.8% 2/17
Abbreviations are as follows: ADHD ¼ attention deficit hyperactivity disorder.
aIndividual 14 is still too young to determine her development.
bTwo individuals had double diagnoses of ADHD and autism spectrum disorder.
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KDM3B is part of an important group comprising the
histone lysine methylases (KMTs) and histone lysine de-
methylases (KDMs). This group of proteins is involved in
gene regulation and expression.23 Several of these genes
have already been associated with NDDs; for example,
KMT2D (MIM: 602113) is associated with Kabuki syn-
drome 1 (MIM: 147920 24)], and KDM6A (MIM: 300128)
is associated with Kabuki syndrome 2 (MIM: 300867 25).
In addition, germline variants in the H3K9 demethylase
JMJD1C (MIM: 604503), which is a gene that shows large
regions of homology with KDM3B, are found in individ-
uals with intracranial germ cell tumors and with
NDDs.26,27 Rare de novo KDM3B variants (c.4216C>T
[p.Arg1406Trp]28 and c.2624del [p.Leu875Argfs*8])4 have
been reported in two individuals with schizophrenia and
ID, respectively. However, the associated phenotypes
have not been fully reported, nor was the causality of these
variants confirmed. None of the individuals presented in
this study showed signs of schizophrenia.
Faundes et al. recently published an overview of all
KMTs and KDMs associated with disease, and they
showed that in these genes, variants resulting in develop-
mental disorders mostly exert their effect through haploin-
sufficiency.23 We identified nonsense variants in five
Figure 2. Facial Characteristics of Individuals Carrying Germline Variants in KDM3B
Presented are frontal and lateral photographs of 10 of the 17 individuals with a variant in KDM3B. Shared facial characteristics include
long ears, a prominent nasal tip, a low columella, a thin upper lip, a broad mouth, and a prominent chin.
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individuals (Table 1), implying that haploinsufficiency is
the most likely mechanism of disease in our individuals
as well. Furthermore, in this paper by Faundes et al.,
KDM3B is among the genes suggested as candidate genes
for NDDs on the basis of the high probability of loss-of-
function intolerance (pLI) score of 1.00 in the ExAC data-
base. Additionally, in ExAC a Z score of 4.99 was reported,
demonstrating a selection against missense variants.
Besides these five individuals with nonsense variants,
there were 12 individuals who carried missense variants
in KDM3B. Notably, two individuals carried missense vari-
ants affecting the same amino-acid; these variants were
c.2827C>T (p.Arg943Trp) in individual 8 and c.2828G>A
(p.Arg943Gln) in individual 9. All missense variants affect
residues that are evolutionarily highly conserved across
other species (Table 1). To further determine the effect of
the missense variants identified, we used the MetaDome
web server to generate a tolerance landscape of KDM3B
(Figure 1B).30 This server uses the gnomAD database to
calculate a missense-over-synonymous ratio as a sliding
window over the protein. This ratio is then expressed as
a tolerance landscape. Herewith, we showed that the
Arg943, Leu1509, Glu1731, and Leu1734 variants are
located in regions intolerant for missense variation, and
the regions surrounding the amino acids Asp1028,
Asp1032, and Tyr1544 are highly intolerant regions for
missense variation (Table 1). The localization of these var-
iants in intolerant and highly intolerant regions of the
gene contributes to the evidence that these variants
are pathogenic; it has been described before that variants
in gene regions that are depleted of missense variation
are more likely to underlie disease.31 According to the
MetaDome tolerance landscape, the regions where the
Trp117 and Asp336 variants are localized are neutral and
tolerant, respectively, meaning that missense variation in
these regions is less rare. However, the facial recognition
software showed that the faces of the individuals with
these two variants do show significant similarity with
those of the other individuals. We consider the Trp117
and Asp336 variants as VUSs that require further study.
Additionally, we show that the mutated amino acids in
the affected individuals are conserved across the other
KDM3 family members, KDM3A (MIM: 611512) and
JMJD1C (Figure 1C); this conservation highlights the
potential importance of these specific amino acids. More-
over, the variants clustered within or near two functional
domains: the zinc-finger and Jumonji-C domains (Figures
1A and 1C).29 The Jumonji-C domain in KDM3B is
responsible for the demethylation of histone 3 lysine 9
(H3K9), and it is a highly conserved domain that
has 64% overall amino acid similarity among KDM3 sub-
family members.29,32,33
Furthermore, because KDM3B is involved in the deme-
thylation of H3K9, we assessed the mono- and tri-methyl-
ation status of H3K9 in HEK293 cells that were overex-
pressing wild-type and missense mutants of KDM3B, but
these experiments were inconclusive due to large vari-
ability in expression levels (data not shown). Therefore,
the functional impact of the missense variants identified
remains to be clarified.
This disorder caused by germline variants in KDM3B
appears to be characterized by a variable clinical presenta-
tion. Short stature (<2.5 SD) was observed in eight
individuals (50.0%). Remarkably, kdm3b-knockout mice
present with a somatic growth restriction, possibly ex-
plained by decreased concentrations of insulin-like growth
factor-1 (IGF1).34 As low IGF1 levels can be indicative of
growth-hormone deficiency, this might be an explanation
for the short stature observed in the individuals with a
variant in KDM3B. IGF1 levels and growth hormone status
were not routinely tested in the individuals described in
this paper, but one child (individual 13) was found to
have isolated growth-hormone deficiency. Also, it is hy-
pothesized by Faundes et al.23 that variants in genes pro-
moting transcriptional activity appear to cause growth
retardation, whereas overgrowth results from variants in
transcriptional repressors such as NSD1 (MIM: 606681)
and EZH2 (MIM: 601573). Because methylation of H3K9
is generally considered to be a repressive mark, demethyla-
tion of H3K9 by KDM3B is predicted to result in the activa-
tion of transcription and thus might explain subsequent
growth retardation. Another feature shown by kdm3b-
knockout mice is subfertility in male mice.35 In accor-
dance, oligospermia was diagnosed in individual 16.
Two individuals were diagnosed with childhood cancer:
acute myeloid leukemia at age 13 in individual 2 and
Hodgkin lymphoma at age 17 in individual 11. In individ-
ual 2, we excluded loss-of-heterozygosity (LOH) of the
Figure 3. t-SNE Plots Showing the Distribution of 13 Individuals
with a Germline Variant in KDM3B Versus Controls with Intellec-
tual Disability
t-distributed stochastic neighbor embeddings (t-SNE) plots visu-
alize the distribution of the hybrid feature vectors for both individ-
uals and controls. Relative clustering of individuals with a germ-
line variant in KDM3B suggests that this group of individuals
with intellectual disability (ID) shows more similarity in facial fea-
tures than is expected by chance. The control group is matched
with the KDM3B-mutated group for gender, ethnicity, and age.
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germline variant and the possibility of a second hit variant
in KDM3B. These individuals have been described
previously in a study focusing on genetic predisposition
for childhood cancer. In this study, we performed
exome sequencing on children with cancer and
additional features pointing toward genetic predisposi-
tion.36 Interestingly, many syndromes, such as Weaver
syndrome (MIM: 277590),37,38 Rubinstein Taybi syndrome
(MIM: 180849),39,40 and Sotos syndrome (MIM:
117550),41,42 caused by variants in other chromatin-re-
modeling genes have been described to cause both ID
and a mildly increased risk of cancer. Because only two
out of 17 individuals in our cohort developed cancer, and
both were recruited through a childhood cancer predispo-
sition study36 (introducing an ascertainment bias), it is un-
clear whether the variants in KDM3B are causative of the
cancer in these children. However, there are several clues
linking variants in KDM3B to cancer predisposition. For
example, somatic variants in KDM3B have been described
in different cancer types,43,44 and several studies link
KDM3B alterations to defects and malignancies in the he-
matopoietic system.32,45–47 Particularly interesting is the
fact that kdm3b-knockout mice show defects in the he-
matopoietic system, consistent with myelodysplastic syn-
drome.48 Together, these facts suggest that KDM3B might
play a role in the development of hematopoietic malig-
nancies. However, the assessment of larger cohorts of
KDM3B-mutated individuals is required to establish
whether the incidence of (hematologic) malignancies is
indeed enriched in these individuals. On the basis of the
current findings, we would not advise screening for malig-
nancies, although vigilance is warranted.
In conclusion, by using exome sequencing we identified
17 individuals with germline, pathogenic variants in
KDM3B. We show that both de novo and inherited variants
in KDM3B cause a syndrome hallmarked by DD or mild to
moderate ID, short stature, and feeding difficulties in in-
fancy. By performing analysis of photographs of the
affected individuals with a hybrid facial recognition
model, we showed that individuals with a variant in
KDM3B significantly cluster within a group of ID-affected
individuals and thus show a facial gestalt. This model
can be used in the future to delineate genetic entities and
determine the pathogenicity of VUSs.
Supplemental Data
Supplemental Data can be found online at https://doi.org/10.
1016/j.ajhg.2019.02.023.
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